Evidence map›Paper›PMID 30220055›Full record

ArticleBreast cancer research and treatment2018

Effectiveness and tolerability of neoadjuvant pertuzumab-containing regimens for HER2-positive localized breast cancer.

Laura Spring, Andrzej Niemierko, Stephanie Haddad, Megan Yuen, Amy Comander, Kerry Reynolds, Jennifer Shin, Atul Bahn, Elena Brachtel, Michelle Specht and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Breast cancer research and treatment, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.8field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 22 citations in OpenAlex.

  1. Predicting the Effectiveness of 2 Chemotherapy Regimens Applied to Breast Cancer Patients by Nutritional and Inflammatory Status.Medical science monitor : international medical journal of experimental and clinical research · 2026
    Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 1 institution in 1 country.

Laura SpringMassachusetts General Hospital Cancer Center, Harvard Medical School, 55 Fruit St., Boston, MA, 02114, USA.ORCID http://orcid.org/0000-0001-8904-3514
Andrzej NiemierkoMassachusetts General Hospital Cancer Center, Harvard Medical School, 55 Fruit St., Boston, MA, 02114, USA.
Stephanie HaddadMassachusetts General Hospital Cancer Center, Harvard Medical School, 55 Fruit St., Boston, MA, 02114, USA.
Megan YuenMassachusetts General Hospital Cancer Center, Harvard Medical School, 55 Fruit St., Boston, MA, 02114, USA.
Amy ComanderMassachusetts General Hospital Cancer Center, Harvard Medical School, 55 Fruit St., Boston, MA, 02114, USA.
Kerry ReynoldsMassachusetts General Hospital Cancer Center, Harvard Medical School, 55 Fruit St., Boston, MA, 02114, USA.
Jennifer ShinMassachusetts General Hospital Cancer Center, Harvard Medical School, 55 Fruit St., Boston, MA, 02114, USA.
Atul BahnMassachusetts General Hospital Cancer Center, Harvard Medical School, 55 Fruit St., Boston, MA, 02114, USA.
Elena BrachtelMassachusetts General Hospital Cancer Center, Harvard Medical School, 55 Fruit St., Boston, MA, 02114, USA.
Michelle SpechtMassachusetts General Hospital Cancer Center, Harvard Medical School, 55 Fruit St., Boston, MA, 02114, USA.
Barbara L SmithMassachusetts General Hospital Cancer Center, Harvard Medical School, 55 Fruit St., Boston, MA, 02114, USA.
Alphonse TaghianMassachusetts General Hospital Cancer Center, Harvard Medical School, 55 Fruit St., Boston, MA, 02114, USA.
Rachel JimenezMassachusetts General Hospital Cancer Center, Harvard Medical School, 55 Fruit St., Boston, MA, 02114, USA.
Jeffrey PeppercornMassachusetts General Hospital Cancer Center, Harvard Medical School, 55 Fruit St., Boston, MA, 02114, USA.
Steven J IsakoffMassachusetts General Hospital Cancer Center, Harvard Medical School, 55 Fruit St., Boston, MA, 02114, USA.
Beverly MoyMassachusetts General Hospital Cancer Center, Harvard Medical School, 55 Fruit St., Boston, MA, 02114, USA.
Aditya BardiaMassachusetts General Hospital Cancer Center, Harvard Medical School, 55 Fruit St., Boston, MA, 02114, USA. Bardia.Aditya@mgh.harvard.edu.
Harvard University · US

Funding

Harvard Clinical and Translational Science CenterUL1TR001102 · NCATS · HARVARD MEDICAL SCHOOL · PI NADLER, LEE MARSHALL · 2013 to 2017
$106.2M
Dana Farber/Harvard Cancer Consortium Career Development Program in Clinical OncologyK12CA087723 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI David Tsai Ting · 2002 to 2026
$17.9M
Harvard Clinical and Translational Science CenterKL2TR001100 · NCATS · HARVARD MEDICAL SCHOOL · PI NADLER, LEE MARSHALL · 2013 to 2017
$8.5M
National Institutes of Health (US) KL2 TR001100NCATS NIH HHS KL2 TR001100NCATS NIH HHS UL1 TR001102NCI NIH HHS K12 CA087723Susan G. Komen for the Cure CCR15224703
6 · The paper itself

Abstract

purposeBased on improvement in pathologic complete response (pCR) in the NeoSphere and TRYPHAENA studies, the FDA approved neoadjuvant pertuzumab for HER2+ localized breast cancer. These studies demonstrated high pCR rates with THP (docetaxel + HP), FEC (5-fluorouracil, epirubicin, and cyclophosphamide)-THP, and TCHP (docetaxel, carboplatin + HP). However, in the United States, doxorubicin/cyclophosphamide (AC) is favored over FEC despite no data comparing neoadjuvant AC-THP with AC-TH or TCHP. Here we report outcomes for patients with localized HER2+ breast cancer treated with pertuzumab-containing neoadjuvant regimens and AC-TH.

methodsWe reviewed clinicopathological characteristics of patients with HER2+ breast cancer (Stage I-III) treated with either a neoadjuvant pertuzumab-containing regimen or dose-dense (dd) AC-TH, from 2011 to 2016 at a large academic medical institution and two affiliated community sites. pCR was defined as ypT0/is ypN0. Fisher's exact test and logistic regression analysis were used for statistical analysis.

resultsIn this study (N = 121), pCR was numerically higher with pertuzumab-based regimens, including ddAC-THP (60%), TCHP (63%), THP (55%), as compared with ddAC-TH (46%). THP resulted in significantly less cycle delays due to toxicity compared to the other regimens (p = 0.02). THP also resulted in the least dose reductions, lowest rate of hospitalization, and lowest rate of treatment discontinuation.

conclusionsPertuzumab-based regimens, including THP, resulted in higher pCR rates as compared to ddAC-TH, with the THP regimen associated with the best tolerability among patients with localized HER2+ breast cancer. Given the various neoadjuvant regimens, additional studies are needed to determine optimal treatment sequencing and escalation/de-escalation strategies to personalize neoadjuvant regimens for localized HER2+ breast cancer.

Indexed as

AdultAgedAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsBreast NeoplasmsErb-b2 Receptor Tyrosine KinasesFemaleHumansMiddle AgedNeoadjuvant TherapyStroke VolumeVentricular Function, LeftAntibodies, Monoclonal, HumanizedERBB2 protein, humanErb-b2 Receptor Tyrosine KinasespertuzumabHER2NeoadjuvantPathologic complete responsePertuzumabTrastuzumab

Identifiers

PMID30220055
PMCPMC6235701
OpenAlexW2891322329

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.